株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):パイプライン分析

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 237879
出版日 ページ情報 英文 108 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):パイプライン分析 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016
出版日: 2016年08月24日 ページ情報: 英文 108 Pages
概要

特発性血小板減少性紫斑病(ITP)は、血小板数が減少し、出血しやすくなる疾患です。この疾患の症状には、 切り傷からの出血が止まりにくい、鼻からの突発的な出血、血尿や血便、歯茎からの出血、倦怠感などがあります。ITPの代表的な治療法には、副腎皮質ホルモン(コルチコステロイド)や免疫抑制剤の投与があります。

当レポートでは、世界においてパイプライン中にある特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)治療薬の概要を提供しており、現在の開発パイプラインの状況や最新動向、後期段階および中止されたプロジェクトの情報、主要企業および彼らが開発中の製品のレビューなどをお届けします。

イントロダクション

  • 調査範囲

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):企業で開発中の治療薬

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):大学/機関で研究中の治療薬

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):企業で開発中の製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):大学/機関で研究中の製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病)の治療薬開発に従事している企業

  • 3SBio Inc.
  • Amgen Inc.
  • Baxalta Incorporated
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • エーザイ
  • Hansa Medical AB
  • Immunomedics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Momenta Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • PhytoHealth Corporation
  • Protalex, Inc.
  • Rigel Pharmaceuticals, Inc.

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 自己免疫疾患・炎症向け阻害剤
  • avatrombopag
  • BI-655064
  • BMS-986004
  • eltrombopag olamine
  • eltrombopag olamine
  • fostamatinib disodium
  • GL-2045
  • GSK-2285921
  • Hetrombopag Olamine
  • MK-8723
  • PBF-1509
  • PHN-013
  • PRTX-100
  • 自己免疫疾患向け免疫グロビンG阻害組み換え酵素
  • romiplostim
  • romiplostim のバイオシミラー
  • SM-101
  • thrombopoietin
  • veltuzumab

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):最近のパイプライン動向

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):休止中のプロジェクト

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):開発が中止された製品

特発性血小板減少性紫斑病(免疫性血小板減少性紫斑病):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8392IDB

Summary

Global Markets Direct's, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016', provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
  • The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects
  • The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview
  • Therapeutics Development
    • Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • AkaRx Inc
    • Amgen Inc.
    • arGEN-X BV
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Genosco
    • Hansa Medical AB
    • Immunomedics, Inc.
    • Intas Pharmaceuticals Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Merck & Co., Inc.
    • Momenta Pharmaceuticals, Inc.
    • Novartis AG
    • Pfizer Inc.
    • PhytoHealth Corporation
    • Protalex, Inc.
    • Rigel Pharmaceuticals, Inc.
    • Shire Plc
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibody for Autoimmune Disorders and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARGX-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avatrombopag - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-655064 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eltrombopag olamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eltrombopag olamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fostamatinib disodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GL-2045 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2285921 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hetrombopag Olamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-281 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-8723 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PHN-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRTX-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romiplostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romiplostim biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKIO-703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • thrombopoietin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veltuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder
      • May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association
      • Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP
      • Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
      • Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag
      • Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP
      • Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
      • Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
      • Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder
      • Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade)
      • Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta)
      • Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
      • Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan
      • Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib
      • Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by AkaRx Inc, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by arGEN-X BV, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics, Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Merck & Co., Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PhytoHealth Corporation, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex, Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2016
  • Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top